Advertisement

Chromatographia

, 66:595 | Cite as

A Validated Stability Indicating RP-LC Method for Nitazoxanide, a New Antiparasitic Compound

  • Ashok S. Jadhav
  • Dnyandeo B. Pathare
  • Murlidhar S. Shingare
Full Short Communication

Abstract

The present paper describes stability indicating reverse phase high-performance liquid chromatography (RP-HPLC) assay method for nitazoxanide in bulk drugs. The developed method is also applicable for the related substances determination in bulk drug. The drug substance was subjected to stress conditions of hydrolysis, photolysis and thermal degradation. The considerable degradation of nitazoxanide was observed under base and peroxide hydrolysis. The drug was found to be stable in other stress conditions attempted. The chromatographic separation of the drug was achieved on reversed-phase C-18 column. Eluents were monitored on photo-diode array detector at a wavelength of 240 nm. The mobile phase was aqueous 0.005 M tetra butyl ammonium hydrogen sulphate and acetonitrile (45:55, v/v). In the developed HPLC method, resolution between nitazoxanide and its potential impurities, namely Imp-A (5-nitro-1,3-thiazol-2-amine), Imp-B (N-(5-nitro-1,3-thiazol-2-yl) acetamide) and Imp-C (2-{[(5-nitro-1,3-thiazol-2-yl) amino] carbonyl} phenyl 2-(acetyloxy) benzoate) was found greater than three. The developed RP-HPLC method was validated with respect to response function, accuracy, precision, specificity, stability of analytical solutions and robustness. Also to determine related substances and assay determination of nitazoxanide that can be used to evaluate the quality of regular production samples. The developed method can also be conveniently used for the assay determination of nitazoxanide in pharmaceutical formulations.

Keywords

Column liquid chromatography Solution and mobile phase stability Validation Nitazoxanide 

Notes

Acknowledgments

The authors wish to thank the management of the Wockhardt group for providing the drugs. We would also like to thank the Process Research Group for important discussions in carrying out this work.

References

  1. 1.
    Montage DE, Ramirez JE, Bernai R (2003) Am J Trop Med Hyg 68:384–385Google Scholar
  2. 2.
    Bobak DA (2006) Curr Infect Dis Rep 8:91–95CrossRefGoogle Scholar
  3. 3.
    White AC Jr (2003) Am J Trop Med Hyg 68:382–383Google Scholar
  4. 4.
    Physicians’ Desk Reference (2005) (eds) Thomson PDR at Montvale, New Jersey, pp 2958–2959Google Scholar
  5. 5.
  6. 6.
    Kapse GK, Prabhakar G, Raju S (2006) Indian J Pharm Sci 68:403–406CrossRefGoogle Scholar
  7. 7.
    Wang Ning, Xia Lin, Hsueh liang, Sen Trees (2004) Chin J Pharm Anal 24:247–249Google Scholar
  8. 8.
    Ph Hubert (2004) J Pharm Biomed Anal 36:579–586Google Scholar
  9. 9.
    ICH (1995) Draft guidelines on validation of analytical procedures: definitions and terminology. Federal Register, vol.60, IFPMA, Switzerland, pp 11260Google Scholar
  10. 10.
    ICH (2000) Stability testing of new drug substances and products (Q1AR). International conference on harmonization, IFPMA, GenevaGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlag/GWV Fachverlage GmbH 2007

Authors and Affiliations

  • Ashok S. Jadhav
    • 1
  • Dnyandeo B. Pathare
    • 1
  • Murlidhar S. Shingare
    • 1
  1. 1.Department of ChemistryDr. B. A. Marathawada UniversityAurangabadIndia

Personalised recommendations